Next-generation Water Systems in Pharma
Fine-tuning AI Models for Molecular Co-folding
Microbiological QC Bottlenecks in Biopharma
Breaking Barriers in bioanalytical automation
Redefining Pharmaceutical Research and Training with Digital Twins and AI
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Engineering the Future of Pneumococcal Conjugate Vaccines (PCV)
PhD, Chemical and Biotechnology, Savitribai Phule Pune University. Manager-Manufacturing, Inventprise Inc
Walmik Karbhari Gaikwad PhD is a seasoned biopharmaceutical expert with years in vaccine RD and manufacturing His PhD research pioneered costeffective processes for pneumococcal conjugate vaccines holds scholarly publications international patents and serves on editorial boards Based in Seattle currently works on cGMPcompliant process development and production at Inventprise Inc
Articles
5 Proven Ways to Take PBM’s to the Future ‘Today’ with Conversational AI
Gone are those if youre still thinking of keeping your customers engaged with your brand by merely sending emails messages phone calls or mobile apps They are expecting way beyond that today It begs the question Is the rapid evolution of selfservice tools creating the need to expect more and more
Research Insights
Microsimulation Based Quantitative Analysis of COVID-19 Management Strategies
Pandemic management requires reliable and efficient dynamical simulation to predict and control disease spreading The COVID SARSCoV pandemic is mitigated by several nonpharmaceutical interventions but it is hard to predict which of these are the most effective for a given population
Case Studies
Viral Clearance For Biopharmaceutical Downstream Processes
Abstract Viral clearance studies are mandated prior to entering clinical trials and for commercial launch of biopharmaceuticals These studies are a key component of risk mitigation to reduce the potential for iatrogenic transmission of pathogenic viruses This paper reviews regulatory guidance and practical strategies for designing viral clearance studies Ess
Techno Trends
Aeglea BioTherapeutics Launches Investigational Therapy for Treatment of ARG1-D
Pegzilarginase an investigational therapy has been launched by Aeglea BioTherapeutics for the treatment of Arginase Deficiency ARGD Pegzilarginase is an enhanced human arginase that is intended for use as an enzyme replacement therapy in patients to reduce the elevated blood arginine levels
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Is Convex Dose Dependence A Side Effect That Multiple Drug Treatment Causes?
Y-h. Taguchi obtained Dr. Sci. of Physics from Tokyo Institute of Technology. He has published papers in major journals, including Scientific Reports and PLoS ONE,a monograph from Springer International and is serving as academic editors in journals including PLoS ONE, BMC Medical Genomics and Frontiers in Genetics:RNA.
TurkiTurki received a PhD in computer science from the New Jersey Institute of Technology. He has published papers in journals, including Expert Systems with Applications, Knowledge-Based Systems, and PLoS ONE. Dr. Turki is an editorial board member of Computers in Biology and Medicine and Sustainable Computing: Informatics and Systems.
AI Cures
Anuradha Singh is an Assistant professor at the Department of Chemistry, S Khanna Girls’ Degree College, University of Allahabad. She is well versed in synthetic chemistry, computer-aided drug design and other techniques used in the field of medicinal chemistry. Dr Singh has published more than 30 research papers/book chapters, in addition to several articles, in journals/books of national and international repute. She has been selected for the prestigious Indian National Science Academy's Visiting Scientist fellowship in 2023. She is a member of several national bodies and referee to various national/ international journals. She successfully led research projects funded by DST and UGC, demonstrating strong leadership and project management skills.
3D Printing
Stéphane Roulon is a pharmaceutical entrepreneur with over ten years of experience in developing 3D printing technologies for drug manufacturing. He is the CEO of MB Therapeutics, a pharmaceutical establishment specializing in personalized medicines produced using advanced 3D printing solutions to support the future of precision medicine.
Innovative Tool For Drug Design And Development
S.Subash awarded 2 best poster presentation awards and secured 1st place in Poster presentation. I published three articles in national and international peer reviewed journal. And, also attend many conferences to upgrade knowledge.
APAC’s Rising Role in Neurodegenerative Disease Research and Development
Simona Lambertini is a senior global clinical research leader with nearly 20 years of experience in international clinical development, research strategy and stakeholder engagement. She has led complex multicountry programs across Europe, North America and the Middle East, collaborating with pharma, biotech and research institutions across high-complexity therapeutic areas.
press releasesRead more...
Everest Medicines Announces China NMPA Acceptance of the Biologics License Application for LEROCHOL® in Adults with Hypercholesterolemia
Everest Medicines HKEX HK Everest or the Company a biopharmaceutical company focused on the discovery clinical development manufacturing and commercialization of innovative therapeutics
Everest Medicines Announces NMPA Acceptance of the BLA for LEROCHOL(R), Offering a Potential New Treatment Option for Hypercholesterolemia in China
Everest Medicines today announced that Chinas National Medical Products Administration NMPA accepted the Biologics License Application BLA for LEROCHOLR lerodalcibep a thirdgeneration PCSK inhibitor
Peptron Enters into Co-Research Agreement with Swiss-Based Debiopharm on Next-Generation ADCs, Validating the Broader Potential of PAb001
Peptron an innovative peptidebased drug development company announced that it has entered into a coresearch agreement with Debiopharm Debiopharm Research Manufacturing SA a Swissbased global biopharmaceutical
UniXell Biotechnology Secures FDA IND Clearance for UX-DA003, Achieving China-U.S. Dual Breakthrough in iPSC Parkinson's Therapy
UniXell Biotechnology Co Ltd UniXell has secured Investigational New Drug IND clearance from the US Food and Drug Administration FDA for UXDA its allogeneic induced pluripotent stem cell iPSCderived therapy
WuXi Biologics’ 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
WuXi Biologics HK a leading global Contract Research Development and Manufacturing Organization CRDMO announced that its MFG drug substance facility located at the Shanghai Fengxian
ATLATL and Samsung Bioepis Launch 'Samsung Bioepis Innovation Prize C-Lab Outside' to Accelerate Early-Stage Biotech Innovation Across Asia-Pacific
TLATL Innovation Center ATLATL a global innovation platform for life science research and development and Samsung Bioepis Co Ltd today announced the launch of the Samsung Bioepis Innovation Prize CLab Outside
EventsRead more...
07 - 09
Jul 2026The Pharma India Expo 2026
Bombay Exhibition Centre, Mumb...
07 - 09
Jul 2026Nanosciences and Nanotechnologies 2026
Thessaloniki, Greece
08 - 10
Jul 2026CPHI SEA 2026
QSNCC, Bangkok, Thailand
09 - 11
Jul 2026Pharma Pro&Pack Expo 2026
HITEX Exhibition Centre, Hyder...
16 - 19
Jul 2026Bio Asia Taiwan 2026
Taipei Nangang Exhibition Cent...
20 - 22
Jul 20266th mRNA-Based Therapeutics Summit
The Westin Boston Seaport Dist...
20 - 22
Jul 2026Liquid Biopsy for Precision Oncology Summit
Boston, MA, USA
24 - 25
Jul 2026Cardiovascular Medicine Pharmacology 2026
Paris, France
LATEST NEWSRead more...
Ionis Licenses Zilganersen Rights Outside US to Recordati
Ionis Pharmaceuticals has signed a licensing agreement with Recordati granting the company exclusive rights to develop and commercialise the investigational medicine zilganersen for Alexander disease AxD
TRYNGOLZA Approved by FDA for Severe Hypertriglyceridaemia Treatment
Ionis Pharmaceuticals has received approval from the US Food and Drug Administration FDA for TRYNGOLZA olezarsen as an adjunct to diet for reducing triglyceride levels and lowering the risk of acute pancreatitis
AstraZeneca and YMCA of the USA Launch Five-Year Partnership to Improve Cancer Care Access
AstraZeneca and YMCA of the USA have announced a fiveyear partnership aimed at improving cancer education increasing awareness of screening and early detection and expanding support for cancer survivors across the United States
Passage Bio and Remix Therapeutics Agree Merger to Advance RNA-Targeted Drug Development
Passage Bio and Remix Therapeutics have entered into a definitive merger agreement in an allstock transaction that will combine the two biotechnology companies Following completion of the deal the merged business
Abbisko Therapeutics Expands Research Partnership with Lilly
Abbisko Therapeutics has entered into a strategic research collaboration and licence agreement with Lilly to discover and develop innovative medicines across multiple disease targets The partnership aims to advance
HighRes and Waters Partner to Enhance Drug Discovery Automation
HighRes has announced a strategic collaboration with Waters Biosciences formerly BD Biosciences to introduce robotic automation capabilities for flow cytometry workflows supporting research activities from basic science to drug discovery
